Author:
Thayu Meena,Chandler Wayne L.,Jelacic Srdjan,Gordon Carrie A.,Rosenthal Geoffrey L.,Tarr Phillip I.
Publisher
Springer Science and Business Media LLC
Subject
Nephrology,Pediatrics, Perinatology, and Child Health
Reference19 articles.
1. Wong CS, Jelacic S, Habeeb RL, Watkins SL, Tarr PI (2000) The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Engl J Med 342:1930–1936
2. Tsai HM, Chandler WL, Sarode R, Hoffman R, Jelacic S, Habeeb R, Watkins SL, Wong CS, Williams GD, Tarr PI (2001) von Willebrand factor and von Willebrand factor-cleaving metalloprotease activity in Escherichia coli O157:H7-associated hemolytic uremic syndrome. Pediatr Res 49:653–659
3. Habib R (1992) Pathology of the hemolytic uremic syndrome. In: Kaplan BS, Trompeter RS, Moake JL (eds) Hemolytic uremic syndrome and thrombotic thrombocytopenic purpura. Dekker, New York, pp 315–353
4. Chandler WL, Jelacic S, Boster DR, Ciol MA, Williams GD, Watkins SL, Igarashi T, Tarr PI (2002) Prothrombotic coagulation abnormalities associated with Escherichia coli O157:H7 infections. N Engl J Med 346:23–32
5. Bergstein JM, Riley BS, Bang NU (1992) Role of plasminogen-activator inhibitor type 1 in the pathogenesis and outcome of the hemolytic uremic syndrome. N Engl J Med 327:755–759
Cited by
39 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献